FIELD: medicine.
SUBSTANCE: invention relates to a medically acceptable compound of formula I 
I or a pharmaceutically acceptable salt thereof, where M and M2 are selected from
or M together with A forms a ring, or M2 together with A2 forms a ring as shown below: 
where Y1 is -O- or -O(C1-C4aliphatic)-group, Y2 is -O(C1-C4aliphatic)-group; Y3 is -O-; Z2, Z3, Z4 and Z6 are OH or F; and one of Z2, Z3, Z4 and Z6 is F; X1 is C1-3alkyl; X2 is H, C1-C10aliphatic group, -U2-V2 or -U2-V2-Q; U2 is -(CH2)q-; V2 is C1-C10aliphatic group, where up to four methylene units can be optionally replaced by -O-, -NR2- or -C (O)-; Q is a 5-6-membered partially unsaturated or aromatic ring having 0–3 nitrogen atoms; where is X2 is optionally substituted by C1-C10aliphatic group, where up to three methylene units C1-C10aliphatic groups may be optionally be replaced by -O-; every X3, X4, X5 and X6 independently is H or C1-C3alkyl, provided that one of X2, X3, X4, X5 and X6 is not H; ring A is C6-10aryl or 5–10-membered heteroaryl, where heteroaryl contains 1 heteroatom selected from oxygen or nitrogen; ring A2 is not necessarily absent or is C6aryl; Z is -C≡C- or ring B is substituted (JB)n; ring B is C3cycloalkyl, 6–9-membered heterocyclyl, C6aryl or 6–9-membered heteroaryl, wherein said heterocyclyl or heteroaryl independently contains 1 nitrogen atom; every JA and JA2 independently is halogen, oxo, CN or C1-C6aliphatic group, where up to one methylene unit C1-C6alkyl may optionally be replaced with -O-, -C(O)- or –NR; JA and JA2 are optionally substituted in 1–3 positions with halogen, and JB represents halogen, CN, NO2, C3cycloalkyl, C6aryl, 6-membered heteroaryl, (C3cycloalkyl)-(C1-C6alkyl)-, (5–6-membered heterocyclyl)-(C1-C6alkyl)-, where heterocyclyl or heteroaryl has 1-2 heteroatoms selected from O or N, or C1-C12aliphatic group, where up to four methylene units C1-C12aliphatic group or up to three methylene units C1-C6alkyl may optionally be replaced with -NR, -O, -C(O)- or -S(O)2-; JB is optionally substituted with 1–5 C1-C10aliphatic groups, where up to three methylene units C1-C10aliphatic groups may optionally be replaced by –NR, -O- or -C(O)-; R and R2 each independently are H, C1-C6aliphatic group or C3cycloalkyl; m, n and u are 0, 1, 2 or 3; each t and r are 0 or 1; and p and q are 1 or 2, or the compound of formula I corresponds to the compound of the following formula:
, 
, 
.
EFFECT: proposed is a new compound, effective for the treatment and prevention of urinary tract infection or inflammatory bowel disease, and compositions based on it.
61 cl, 129 ex, 7 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| SECONDARY MANNOSIS FOR BACTERIAL INFECTIONS TREATMENT | 2013 |
|
RU2667060C2 |
| C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | 2011 |
|
RU2606501C2 |
| C-MANNOSIDE COMPOUNDS USED FOR TREATMENT OF URINARY TRACT INFECTIONS | 2019 |
|
RU2790228C2 |
| METHOD FOR PRODUCING DEPHENYLMETHANE DERIVATIVE | 2017 |
|
RU2797392C2 |
| METHOD OF PRODUCING DEPHENYLMETHANE DERIVATIVE | 2023 |
|
RU2814846C1 |
| NEW GLUCITOL DERIVATIVE, PRODRUG AND SALT AND THERAPEUTIC AGENT CONTAINING THEM FOR DIABETES TREATMENT | 2005 |
|
RU2386631C2 |
| C-GLYCOSIDE DERIVATIVES CONTAINING A CONDENSED PHENYL RING, OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, A METHOD OF PRODUCING SUCH AND A PHARMACEUTICAL COMPOSITION CONTAINING SUCH | 2017 |
|
RU2739024C2 |
| β-LACTAMS, METHOD FOR PREPARING INDICATED COMPOUNDS AND SERUM HYPOCHOLESTEROLEMIC AGENTS CONTAINING SUCH COMPOUNDS | 2002 |
|
RU2301799C2 |
| NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG AND SALT THEREOF AND DIABETES THERAPEUTIC AGENT CONTAINING SAID COMPOUNDS | 2005 |
|
RU2394015C2 |
| COMPOSITIONS COMPRISING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 AND METHODS OF USING THEREOF | 2012 |
|
RU2669921C2 |
